Revance Therapeutics (RVNC) Stock Forecast & Price Target

$3.80 +0.04 (+1.06%)

(As of 11/20/2024 ET)

Revance Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold

Based on 9 Analyst Ratings

Sell
0

Hold
8

Buy
1

Based on 9 Wall Street analysts who have issued ratings for Revance Therapeutics in the last 12 months, the stock has a consensus rating of "Hold." Out of the 9 analysts, 8 have given a hold rating, and 1 has given a buy rating for RVNC.

Consensus Price Target

$9.66
154.14% Upside

According to the 9 analysts' twelve-month price targets for Revance Therapeutics, the average price target is $9.66. The highest price target for RVNC is $20.00, while the lowest price target for RVNC is $6.00. The average price target represents a forecasted upside of 154.14% from the current price of $3.80.

Get the Latest News and Ratings for RVNC and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors.

RVNC Analyst Ratings Over Time

Type	Current Forecast 11/22/23 to 11/21/24	1 Month Ago 10/23/23 to 10/22/24	3 Months Ago 8/24/23 to 8/23/24	1 Year Ago 11/22/22 to 11/22/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	1 Buy rating(s)	1 Buy rating(s)	2 Buy rating(s)	6 Buy rating(s)
Hold	8 Hold rating(s)	8 Hold rating(s)	8 Hold rating(s)	2 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$9.66	$10.29	$10.88	$25.33
Forecasted Upside	154.14% Upside	94.44% Upside	64.77% Upside	247.51% Upside
Consensus Rating	Hold	Hold	Hold	Moderate Buy

Tesla Execs are Freaking Out (Ad)

It’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands on it. And Elon Musk has completely restructured Tesla to chase this opportunity. This is a once-in-a-lifetime opportunity that you don’t want to miss.

Click here to get the details.

RVNC Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

RVNC Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Revance Therapeutics Stock vs. The Competition

Type	Revance Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.11	2.80	2.50
Consensus Rating	Hold	Moderate Buy	Moderate Buy
Predicted Upside	154.14% Upside	26,931.53% Upside	9.83% Upside
News Sentiment Rating	Neutral News See Recent RVNC News	Neutral News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
11/8/2024	Needham & Company LLC 2 of 5 stars	S. Belanger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold
11/8/2024	HC Wainwright 2 of 5 stars	D. Tsao Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$6.60 ➝ $6.60	+76.94%
9/13/2024	Barclays 3 of 5 stars	B. Prasad Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$10.00 ➝ $7.00	+6.87%
8/12/2024	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Amsellem Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2024	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	S. Fernandez Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
8/12/2024	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Lugo Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform
Get the Latest News and Ratings for RVNC and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Revance Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
8/9/2024	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$24.00 ➝ $20.00	+577.96%
5/13/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$9.00 ➝ $8.00	+146.91%
5/10/2024	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral ➝ Neutral	$9.00 ➝ $8.00	+86.48%
10/11/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$25.00 ➝ $12.00	+21.83%
8/16/2023	BNP Paribas Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underperform ➝ Neutral	$20.00	+6.38%
3/14/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target		$22.00 ➝ $30.00	+5.41%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 09:26 AM ET.

RVNC Forecast - Frequently Asked Questions

: According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Revance Therapeutics is $9.66, with a high forecast of $20.00 and a low forecast of $6.00.
: 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Revance Therapeutics in the last year. There are currently 8 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" RVNC shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in RVNC, but not buy additional shares or sell existing shares.
: According to analysts, Revance Therapeutics's stock has a predicted upside of 154.14% based on their 12-month stock forecasts.
: Revance Therapeutics has been rated by research analysts at Barclays, HC Wainwright, and Needham & Company LLC in the past 90 days.
: Analysts like Revance Therapeutics less than other "medical" companies. The consensus rating for Revance Therapeutics is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how RVNC compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

This Bull Market Indicator called NVDA at $116 (Ad)

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

This page (NASDAQ:RVNC) was last updated on 11/21/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Revance Therapeutics (RVNC) Stock Forecast & Price Target